reports
- Jacob Mekhael
Pharvaris 2Q25 update shows all is on track, on-demand phase 3 readout...
Pharvaris reported 2Q25 results showing no major surprises and confirming previously communicated timelines, with the next key milestone being topline results from the phase 3 trial of deucrictibant (B2R antagonist, oral tablet) in on-demand HAE in 4Q25 – we are confident in a positive outcome. The company reported a cash position of $ 200m (YE24: $281m), which was supplemented by $ 201m in a public offering in July 2025, providing Pharvaris with a cash runway into 1H27. We continue to see Pharv...
- Jacob Mekhael
- Wim Hoste
- Wim Lewi
Pharvaris Reports Second Quarter 2025 Financial Results and Provides B...
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, on track; study is expected to initiate by YE2025Strong financial position with cash and cash equ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering ...
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the closing of its previ...
- Jacob Mekhael
Pharvaris Raises $ 175m in gross proceeds via public offering
Pharvaris announced the pricing of an upsized public offering of 8,250,000 ordinary shares at a price of $ 20 per share (13.49% discount to previous close), and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $ 19.99 per pre-funded warrant for gross proceeds of approx. $ 175m. We expect the net proceeds to extend Pharvaris' cash runway to mid-2027 (KBCSe) from 2H26, and will be used for R&D as well as commercialisation preparations in the US. We update our ...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of...
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20...
Pharvaris Announces Proposed Public Offering of Ordinary Shares
Pharvaris Announces Proposed Public Offering of Ordinary Shares ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today that it intends to offer and sell $150,000,000 of ordinary shares in an underwritten public offering. All shares in the offering are to be sold b...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BIIB BIOGEN INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
U INC.
VRDN UNITY SOFTWARE
PHVS VIRIDIAN THERAPEUTICS INC
STX PHARVARIS NV
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD APPLOVIN CORP
ATXS THE TRADE DESK
GFS INC.
EWTX ASTRIA THERAPEUTICS INC
GLOBALFOUNDRIES INC
EDGEWISE THERAPEUTICS INC
- Dylan Shindler
- Laura Chico
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
- Thomas Vranken
Pharvaris FIRST LOOK: Accelerated timelines for on-demand HAE treatmen...
Pharvaris has accelerated its timeline for topline data from the RAPIDe-3 Phase 3 trial evaluating deucrictibant for on-demand treatment of hereditary angioedema (HAE), now expected in 4Q25 instead of 1Q26. The study aims to confirm earlier Phase 2 findings and measures time to symptom relief. Pending positive results, Pharvaris plans to submit its FDA application in the first half of 2026. Meanwhile, the company is also advancing its prophylactic HAE program and planning studies in acquired ang...
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Piv...
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated...
- Dylan Shindler
- Laura Chico
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for...
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Associatio...
Pharvaris Presents Data Highlighting the Potential for Deucrictibant t...
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Cli...
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Announces Annual Meeting of Shareholders ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual ...
- Wedbush Research
- Jacob Mekhael
Pharvaris R&D day outlines plans to expand deucrictibant opportunity
Yesterday, Pharvaris hosted an R&D call to discuss plans for deucrictibant (oral B2 receptor antagonist) beyond HAE type 1/2. The company believes that deucrictibant could offer good outcomes for patients with normal C1-INH HAE, and this subset of patients is included in the phase 3 programs for on-demand and prophylaxis. In addition, the company pointed to the potential of deucrictibant to address acquired angioedema (AAE), where no approved treatments exist and investigator results demonstrate...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.